LASOFOXIFENE TARTRATE
Biochem/physiol Actions
Lasofoxifene possesses strong resistance to intestinal wall glucuronidation and thus promotes oral bioavailability. In postmenopausal women, it reduces bone resorption, bone loss and low density lipoprotein (LDL) cholesterol. Selective and regular dose of Lasofoxifene is known to reduce the risk of fractures, breast cancer, major coronary heart disease, and stroke.
Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
Packaging
10, 50 mg in glass bottle
| Colour | white to beige |
|---|---|
| Quality Level | 100 |
| InChI key | INEHJXCWEVNEDZ-LUDNRVPPSA-N |
| InChI | 1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15, |
| Manufacturer | SIGMA-ALDRICH |
| Solubility | DMSO: 10 mg/mL, clear |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
